Boehringer Ingelheim
Clinical trials sponsored by Boehringer Ingelheim, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill zongertinib takes on HER2 lung cancer in major trial Results expected Sep 2026 (estimated)
- New drug aims to boost immune system against tough cancers Results expected Sep 2026 (estimated)
- Can two factories make the same Parkinson's drug? a trial puts it to the test Results expected Sep 2026 (estimated)
- Beyond the lungs: the hidden emotional toll of IPF medications Results expected Sep 2026 (estimated)
- New imaging trial peers inside tumors to track experimental Drug's path Results expected Sep 2026 (estimated)
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Can a new pill ease muscle weakness in myositis?
Disease control Not yet recruitingThis phase III trial tests whether the oral drug nerandomilast can improve symptoms of idiopathic inflammatory myopathies, a group of rare autoimmune diseases that cause muscle weakness and inflammation. Adults with active myositis are randomly assigned to take nerandomilast or a…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
5,000-Patient study tests jardiance against standard heart failure drugs in china
Disease control Not yet recruitingThis study looks at how well the drug Jardiance works compared to other standard heart failure treatments in Chinese patients with a specific type of heart failure (HFrEF). Researchers will track about 5,000 adults to see which treatment better prevents heart failure hospitalizat…
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new injection help tackle obesity? a trial investigates
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BI 3034701 in people with overweight or obesity who also have at least one weight-related health condition. The main goal is to see how safe and tolerable the drug is when given by injection, and to understand how i…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill aims to halt lung scarring in thousands
Disease control Not yet recruitingThis study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows di…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Jardiance under the microscope: new study tracks heart failure outcomes in china
Knowledge-focused Not yet recruitingThis study will observe 3,000 adults in China with a type of heart failure called HFpEF who are starting the drug Jardiance. Researchers will track how many patients are hospitalized for heart failure or die from heart-related causes over time. The goal is to see how effective an…
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Will a common seizure drug alter the fate of an experimental medicine?
Knowledge-focused Not yet recruitingThis phase 1 trial is testing whether carbamazepine, a drug that speeds up liver enzymes, changes how the body absorbs and clears verducatib, an experimental medicine. Healthy male volunteers aged 18 to 50 will take verducatib alone, then with carbamazepine, to compare drug level…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC